Patent ID: 11872249
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a cancer, wherein said method comprises administering to the mammal an effective amount of a plurality of immune effector cells expressing an isolated chimeric antigen receptor (CAR), wherein the plurality of immune effector cells comprise T cells, NK cells, or both T cells and NK cells, wherein the CAR comprises a CD20 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein the CD20 binding domain comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:
(i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;
(ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;
(iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively;
(iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively;
(v) SEQ ID NOs: 228, 229, 230, 217, 218, and 219, respectively;
(vi) SEQ ID NOs: 231, 232, 233, 220, 221, and 222, respectively;
(vii) SEQ ID NOs: 234, 235, 236, 223, 224, and 225, respectively; or
(viii) SEQ ID NOs: 944, 945, 988, 941, 942, and 943, respectively.